Evidence map›Paper›PMID 40166435›Full record

ArticleDiabetology international2025

Relationship of dietary intake and eating behaviors with glycemic control and body weight under long-term treatment with dapagliflozin: an exploratory prospective study.

Hisashi Yokomizo, Daiji Kawanami, Noriyuki Sonoda, Yasuhiro Ono, Yasutaka Maeda, Jun Itoh, Takeshi Tohyama, Masayuki Hirose, Hiroko Watanabe, Junji Kishimoto and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Diabetology international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. New Horizons in Metabolic Health: Unveiling the Future of Drug Discovery and Development.Endocrine, metabolic & immune disorders drug targets · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Hisashi YokomizoDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.ORCID 0000-0001-7759-2014
Daiji KawanamiDepartment of Endocrinology and Diabetes, Fukuoka University School of Medicine, 7-45-1 Nanakuma, Jonan-ku, Fukuoka, 814-0180 Japan.
Noriyuki SonodaSonoda Clinic, Kagoshima, Japan.
Yasuhiro OnoDepartment of Internal Medicine, Takagi Hospital, Fukuoka, Japan.
Yasutaka MaedaMINAMI Diabetes Clinical Research Center, Clinic Masae Minami, Fukuoka, Japan.
Jun ItohDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.
Takeshi TohyamaCenter for Advanced Medical Open Innovation, Kyushu University, Fukuoka, Japan.
Masayuki HiroseCenter for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
Hiroko WatanabeCenter for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
Junji KishimotoCenter for Clinical and Translational Research, Kyushu University Hospital, Fukuoka, Japan.
Yoshihiro OgawaDepartment of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University3-1-1 Maidashi, Higashi-ku, Fukuoka, 812-8582 Japan.
Toyoshi InoguchiFukuoka City Health Promotion Support Center, Fukuoka City Medical Association, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sodium glucose cotransporter-2 (SGLT2) inhibitors improve glycemic control and reduce body weight (BW) in individuals with type 2 diabetes. However, there are still concerns that compensatory hyperphagia may affect their effects. Here, we performed an exploratory prospective study to investigate whether dietary intake and/or eating behaviors affect glycemic control and BW under long-term treatment with dapagliflozin. Fifty-three Japanese individuals with type 2 diabetes received dapagliflozin 5 mg daily for 104 weeks, with frequent assessments of HbA1c, BW, body composition, dietary intake, and eating behaviors. Dietary intake was evaluated using a brief self-administered diet history questionnaire, and eating behavior was evaluated using the Dutch Eating Behavior Questionnaire. The study was registered in the University Hospital Medical Information Network Clinical Trials Registry (UMIN000019192). At 104 weeks, HbA1c decreased by 0.5% and BW decreased by 2.8 kg (both Supplementary Information: The online version contains supplementary material available at 10.1007/s13340-025-00794-1.

Indexed as

Dietary intakeEating behaviorGlycemic controlSGLT2 inhibitorWeight control

Identifiers

PMID40166435
PMCPMC11954782

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.